WeTrials
Recruiting

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

What is this study?

This study is testing a medication called selinexor to see if it can help children and young people with certain hard-to-treat solid tumors, including Wilms tumor and other rare cancers. Researchers want to see if this targeted drug can help stop cancer cells from growing when other treatments haven't worked.

Who can participate?

This study is open to patients starting from toddlers up to adults who have specific types of recurrent or hard-to-treat solid tumors. Participants must be able to follow study rules and provide consent or have a parent/guardian provide it.

What will happen?

Participants will receive the study medication, selinexor, which is designed to block specific proteins inside cancer cells. Doctors will monitor health and safety closely through regular check-ups during the treatment process.

Where and when?

The study is currently recruiting patients at medical centers in Los Angeles, Palo Alto, and Washington D.C. It is an active Phase II trial.

Key Points
  • 1Testing a targeted cancer medicine called selinexor
  • 2For children and young patients with specific hard-to-treat solid tumors
  • 3Currently recruiting at multiple medical centers in the United States

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Wilms TumorRhabdoid TumorMalignant Peripheral Nerve Sheath TumorsMPNSTNephroblastomaXPO1 Gene MutationSolid Tumor

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.